Would you like to participate in a study for idiopathic pulmonary fibrosis (IPF)?

We are inviting you to take part in a study for men and women at least 40 years old, diagnosed with idiopathic pulmonary fibrosis (IPF) in the previous five years. Enrolled patients will receive all study-related procedures, medications, and laboratory services at no cost. In addition, reimbursement for travel may be provided. No health insurance is required.

The GALACTIC-1 study is investigating the safety and efficacy of GB0139, a dry powder, inhaled galectin-3 inhibitor in patients with idiopathic pulmonary fibrosis.

You may qualify for the GALACTIC-1 study if:

  • You are at least 40 years old
  • You have been diagnosed with idiopathic pulmonary fibrosis in the previous five years
Volunteers who take part in the study may receive reimbursement for travel expenses.
Participate
Participate
Participate

Sign Up

What happens if I sign up? We will match you to a study location in your area that needs patients with idiopathic pulmonary fibrosis (IPF) or notify you when one becomes available. The study team will then contact you and you may have the opportunity to participate if qualified.


If you think you might like to participate in the GALACTIC-1 study or would like more information, please enter your information below so we can see if you may qualify and can contact you about the studies. Keep in mind that participation is entirely voluntary. If you do decide to take part in a study, you may change your mind about participating at any time.

About the GALACTIC-1 study

The GALACTIC-1 study will enroll about 141 patients with idiopathic pulmonary fibrosis (IPF) at clinics throughout 11 countries.

Enrolled patients will receive all study-related procedures, medications, and laboratory services at no cost.

The study will include approximately 8 visits to a clinic in your location over approximately 12 months.

Patients who qualify to take part in the study may receive reimbursement for travel expenses.

Who can take part in the GALACTIC-1 study?

You may be able to take part in the study if:

  • You are at least 40 years old
  • You have been diagnosed with idiopathic pulmonary fibrosis in the previous five years

All study-related care is provided by Specialist Physicians.

The GALACTIC-1 study is investigating the safety and efficacy of GB0139, a dry powder, inhaled galectin-3 inhibitor in patients with idiopathic pulmonary fibrosis.

Frequently Asked Questions

What is a research study?

A research study (also called a clinical trial) is a medical study that helps to answer important questions about a study medication – these may include how well an investigational study medication works for a certain condition. All medications must be tested in clinical research studies before they can be approved and prescribed to patients.

The GALACTIC-1 study is a randomized, double-blind, multicenter, parallel, placebo-controlled study in patients with idiopathic pulmonary fibrosis (IPF) investigating the safety and efficacy of GB0139, an inhaled galectin-3 inhibitor administered via a dry powder inhaler over 52 weeks.

Neither the subjects nor their study doctors will know which treatment they receive. Their study doctor can find out which treatment a subject is receiving if the subject’s safety is determined to be at risk.

Approximate recruitment for this study will be about 141 patients total.

All interested patients who decide to participate will be required to sign an Informed Consent form (ICF).

Participants are required to attend a screening visit to determine if they meet the eligibility requirements.

After screening, visits will be scheduled at week 0/baseline, and then at weeks 4, 8, 12, 26, 40, and 52. A follow-up safety assessment will be performed via a phone call approximately one week after the last study visit.

Enrolled patients will receive all study-related procedures, medications, and laboratory services at no cost. Additionally, patients who qualify to take part in the study may receive reimbursement for travel expenses.

There is no cost to participate in the GALACTIC-1 study. If you qualify, you will receive all study-related procedures, medications, and laboratory services at no cost.

If you decide to take part:

  • You will receive study-related care throughout the study from a team of experienced study doctors and nurses
  • You will receive all study-related procedures, medications, and laboratory services at no cost.

The research team will be able to explain more about what the GALACTIC-1 study will involve, and it is up to you to decide if you want to take part. Participation in this study is voluntary. Whether or not you decide to participate in this study will not affect your current or future relationships with your doctors. If you decide to participate, you are free to withdraw at any time without affecting those relationships.

We match you to a clinic within a close travel distance from your home. If we are not running the study in your area currently, with your permission, we will keep you in our database and reach out once a study in your area becomes available. If, at any time, you decided you no longer want your information stored, you can opt out and we will delete your details.

About Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic pulmonary fibrosis, (commonly referred to as IPF) is a lung disease that occurs when the tissue of the lungs and the air sacs (alveoli) of the lungs becomes scarred and damaged. Over time, this scar tissue, called fibrosis makes it difficult for people to breath.1

People who smoke have a much higher risk of developing IPF. The risk also tends to increase with age. Those who have IPF experience their symptoms differently; some may experience the symptoms associated with the scarring that happens with IPF quickly, while the condition progresses more slowly in others.2

Symptoms of IPF may include:

  • Shortness of breath
  • A dry, persistent cough
  • Fatigue
  • Weight loss
  • Clubbing (roundness) of the fingernails and toenails

The GALACTIC-1 study is investigating the safety and efficacy of GB0139, a dry powder, inhaled galectin-3 inhibitor in patients with idiopathic pulmonary fibrosis.